Is JB Chemicals & Pharmaceuticals a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that JB Chemicals & Pharmaceuticals Ltd is a good quality company .

Is JB Chemicals & Pharmaceuticals undervalued or overvalued?

The key valuation ratios of JB Chemicals & Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is JB Chemicals & Pharmaceuticals share price return in the past 10 years?

JB Chemicals & Pharmaceuticals Ltd share price has appreciated 31.5% annually (CAGR) over the past ten years.

Is JB Chemicals & Pharmaceuticals a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of JB Chemicals & Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

What is the P/E ratio of JB Chemicals & Pharmaceuticals?

The latest standalone P/E ratio of JB Chemicals & Pharmaceuticals as of 14-Nov-2024 is 42.99.

What is the P/B ratio of JB Chemicals & Pharmaceuticals?

The latest standalone P/B ratio of JB Chemicals & Pharmaceuticals as of 14-Nov-2024 is 8.17.

What is the 52-week high and low of JB Chemicals & Pharmaceuticals?

The 52-week high of JB Chemicals & Pharmaceuticals is Rs. 2029.00 and the 52-week low is Rs. 1376.95.

What is the TTM revenue of JB Chemicals & Pharmaceuticals?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of JB Chemicals & Pharmaceuticals is Rs. 3517.37 (Cr.).

JB Chemicals & Pharmaceuticals Ltd - Stock Valuation and Financial Performance

Name: JB Chemicals & Pharmaceuticals
Brand: JB Chemicals & Pharmaceuticals

BSE: 506943 | NSE: JBCHEPHARM | Pharmaceuticals & Drugs | Small Cap

Place order

JB Chem & Pharma Share Price

₹1,689.30 -24.55 -1.43%
as on 14-Nov'24 16:59

10 Year X-Ray of JB Chem & Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	14.7%	19.1%	15.7%	12.5%	18.3%	23%	36.3%	24%	22%	25.1%	-
Value Creation Index ⓘ	0.1	0.4	0.1	-0.1	0.3	0.6	1.7	0.8	0.6	1.2	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	1,061	1,165	1,199	1,255	1,501	1,641	1,892	2,190	2,884	3,299	3,517
Sales YoY Gr.	-	9.8%	2.9%	4.7%	19.6%	9.3%	15.3%	15.7%	31.7%	14.4%	-
Adj EPS ⓘ	6.5	8.8	8.7	6.4	10.7	16.7	25.9	21.7	25.5	34.2	38.6
YoY Gr.	-	35.2%	-1.6%	-26.4%	68.5%	55.6%	55.3%	-16.4%	17.4%	34.3%	-
BVPS (₹) ⓘ	59.9	72.1	81.8	87	92.5	93.5	116.9	132.1	150	177	203.3
Adj Net Profit ⓘ	110	149	147	106	172	258	401	335	394	531	600
Cash Flow from Ops. ⓘ	143	171	178	116	193	272	335	147	629	789	-
Debt/CF from Ops. ⓘ	0.7	1	0.3	0.3	0.1	0.1	0.1	0.2	0.8	0.4	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	13.4%	17.1%	20.4%	14.4%
Adj EPS ⓘ	20.2%	26.1%	9.7%	34.3%
BVPSⓘ	12.8%	13.9%	14.8%	18%
Share Price	31.5%	53.5%	26.2%	12.4%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	10.7	13.3	11.3	7.5	11.7	17.6	24.6	17.1	17.3	19.9	20.3
Op. Profit Mgn % ⓘ	18.6	19.6	19	15.9	19.5	22.6	29.2	23.2	23.4	26.6	27.1
Net Profit Mgn % ⓘ	10.4	12.8	12.3	8.5	11.5	15.7	21.2	15.3	13.7	16.1	17.1
Debt to Equity ⓘ	0.1	0.1	0	0	0	0	0	0	0.2	0.1	0
Working Cap Days ⓘ	162	214	276	290	269	224	191	220	203	200	89
Cash Conv. Cycle ⓘ	100	95	96	98	87	81	75	84	73	65	53

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 20.30%

Sales growth is growing at healthy rate in last 3 years 20.36%

Sales growth is good in last 4 quarters at 12.86%

Net Profit has been subdued in last 3 years 9.67%

Latest Financials - JB Chemicals & Pharmaceuticals Ltd.

	Standalone	Consolidated
TTM EPS (₹)	38.6	39.4
TTM Sales (₹ Cr.)	3,517	3,711
BVPS (₹.) ⓘ	203.3	206.8
Reserves (₹ Cr.) ⓘ	3,142	3,197
P/BV ⓘ	8.17	8.03
PE ⓘ	42.99	42.21

From the Market
52 Week Low / High (₹)	1376.95 / 2029.00
All Time Low / High (₹)	2.70 / 2029.00
Market Cap (₹ Cr.)	25,798
Equity (₹ Cr.)	15.5
Face Value (₹)	1
Industry PE ⓘ	43.1

Management X-Ray of JB Chem & Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of JB Chem & Pharma

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of JB Chem & Pharma

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	1,061	1,165	1,199	1,255	1,501	1,641	1,892	2,190	2,884	3,299
Operating Expenses ⓘ	868	939	980	1,073	1,213	1,272	1,340	1,681	2,219	2,422
Manufacturing Costs	276	175	178	189	203	191	197	248	292	308
Material Costs	323	470	469	484	536	569	626	744	1,037	1,109
Employee Cost	147	166	188	217	258	294	306	399	500	565
Other Costs ⓘ	122	129	145	182	215	219	211	290	391	439
Operating Profit ⓘ	193	226	219	182	288	368	552	509	665	877
Operating Profit Margin (%)	18.2%	19.4%	18.2%	14.5%	19.2%	22.4%	29.2%	23.2%	23.0%	26.6%
Other Income ⓘ	10	56	50	56	40	50	116	39	9	37
Interest ⓘ	7	10	5	3	5	3	7	5	34	41
Depreciation ⓘ	38	40	46	56	55	65	67	71	112	135
Exceptional Items ⓘ	0	0	0	0	0	-10	0	0	0	0
Profit Before Tax ⓘ	159	231	217	179	269	340	594	471	527	738
Tax ⓘ	46	51	44	51	87	71	147	110	138	195
Profit After Tax	114	179	173	128	182	268	447	361	389	543
PAT Margin (%)	10.7%	15.4%	14.4%	10.2%	12.1%	16.3%	23.6%	16.5%	13.5%	16.5%
Adjusted EPS (₹)	6.7	10.6	10.2	7.7	11.4	17.4	28.9	23.4	25.1	35.0
Dividend Payout Ratio (%)	105%	24%	5%	13%	22%	32%	29%	35%	35%	35%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	1,016	1,223	1,388	1,453	1,485	1,445	1,806	2,041	2,321	2,746
Share Capital ⓘ	17	17	17	17	16	15	15	15	15	16
Reserves ⓘ	999	1,206	1,371	1,437	1,469	1,430	1,791	2,026	2,305	2,731
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	105	174	49	28	26	29	26	26	390	24
Long Term Debt	0	0	0	0	0	0	0	0	383	24
Short Term Debt	105	174	49	28	26	29	26	26	7	0
Trade Payables	62	69	79	100	111	152	164	196	222	332
Others Liabilities ⓘ	265	539	581	646	705	385	542	735	1,083	1,495
Total Liabilities ⓘ	1,449	2,005	2,097	2,228	2,327	2,012	2,539	2,999	4,015	4,597
Fixed Assets
Gross Block	572	680	964	980	1,012	1,105	1,108	1,797	2,522	2,749
Accumulated Depreciation	271	310	355	410	460	522	544	593	701	824
Net Fixed Assetsⓘ	301	369	609	570	552	583	565	1,204	1,822	1,925
CWIP ⓘ	55	135	4	17	15	16	26	19	55	76
Investmentsⓘ	597	612	544	567	589	536	811	146	339	531
Inventories	128	133	160	176	208	232	279	350	387	461
Trade Receivables	248	266	265	301	300	344	374	518	524	625
Cash Equivalents	9	11	7	15	21	12	26	40	56	64
Others Assetsⓘ	109	479	508	583	641	289	458	723	833	915
Total Assets ⓘ	1,449	2,005	2,097	2,228	2,327	2,012	2,539	2,999	4,015	4,597

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	143	171	178	116	193	272	335	147	629	789
PBT ⓘ	159	231	217	179	269	340	594	471	527	738
Adjustment ⓘ	36	-10	10	15	27	15	-56	97	203	187
Changes in Working Capital ⓘ	-14	1	-0	-40	-42	4	-61	-294	-13	-9
Tax Paid ⓘ	-38	-51	-49	-38	-61	-87	-140	-127	-89	-128
Cash Flow From Investing Activity ⓘ	-122	-52	-42	-24	-28	24	-231	4	-956	-412
Capex	-70	-189	-153	-29	-41	-69	1	-697	-757	-257
Net Investments	-53	117	109	3	10	91	-233	700	-186	-150
Others ⓘ	1	19	2	1	3	2	1	1	-13	-6
Cash Flow From Financing Activityⓘ	-23	-97	-165	-59	-156	-305	-87	-138	343	-374
Net Proceeds from Shares ⓘ	1	0	0	0	0	0	0	0	8	20
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	521	-179
Interest Paid ⓘ	-4	-2	-3	-3	-4	-2	-6	-2	-31	-41
Dividend Paid ⓘ	-30	-188	-6	-10	-21	-141	-73	-128	-128	-157
Others ⓘ	10	92	-156	-46	-131	-163	-7	-8	-28	-17
Net Cash Flow ⓘ	-2	22	-30	32	9	-10	18	13	16	3

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	11.01	16.01	13.25	9.01	12.39	18.3	27.5	18.77	17.83	21.45
ROCE (%)	14.65	19.13	15.65	12.5	18.3	22.96	36.33	24.04	22.02	25.13
Asset Turnover Ratio	0.77	0.67	0.58	0.58	0.66	0.76	0.83	0.81	0.85	0.79
PAT to CFO Conversion(x)	1.25	0.96	1.03	0.91	1.06	1.01	0.75	0.41	1.62	1.45
Working Capital Days
Receivable Days	84	81	81	82	73	72	69	73	64	61
Inventory Days	41	41	45	49	47	49	49	51	45	45
Payable Days	64	51	57	68	72	84	92	88	74	91

JB Chemicals & Pharmaceuticals Ltd Stock News

JB Chemicals & Pharmaceuticals Ltd FAQs

What is the share price of JB Chem & Pharma?

Company share prices are keep on changing according to the market conditions. The closing price of JB Chem & Pharma on 14-Nov-2024 16:59 is ₹1,689.3.

What is the market cap of JB Chem & Pharma?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 14-Nov-2024 16:59 the market cap of JB Chem & Pharma stood at ₹25,797.7.

What is the P/E ratio of JB Chem & Pharma?

The latest P/E ratio of JB Chem & Pharma as of 14-Nov-2024 16:59 is 42.99.

What is the P/B ratio of JB Chem & Pharma?

The latest P/B ratio of JB Chem & Pharma as of 14-Nov-2024 16:59 is 8.17.

What is the 52-week high and low of JB Chem & Pharma?

The 52-week high of JB Chem & Pharma is ₹2,029 and the 52-week low is ₹1,377.

What is the TTM revenue of JB Chem & Pharma?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of JB Chem & Pharma is ₹3,517 ( Cr.) .

About JB Chemicals & Pharmaceuticals Ltd

Established in 1976, J.B.Chemicals & Pharmaceuticals Ltd. (JBCPL) is one of India’s fastest growing pharmaceutical companies. An integrated, research-oriented, public listed organisation with a focus on supplying affordable, quality products both in India and International markets, JBCPL is trusted by healthcare professionals globally.

JBCPL is widely committed to manufacturing a range of innovative specialty products that include various pharmaceutical dosage forms like tablets, injectable (vials, ampoules, form fill seal), creams & ointments, lozenges, herbal liquids and capsules. In India and International markets, JBCPL is also known as Unique Pharmaceutical Laboratories and is a division of JBCPL.

JBCPL exports too many countries worldwide with presence in US, Europe, Australia, South Africa, other developing countries, Russia and CIS. The Company continues to invest in growing its share in the regulated markets such as USA, Europe and Australia. JBCPL has a strong R&D and regulatory set-up for development of new drug delivery system and formulations, filing of ANDAs and DMFs. Its state-of-the-art manufacturing facilities are approved by health authorities of key regulated markets.

Business area of the company

J. B. Chemicals & Pharmaceuticals is engaged in the business of manufacturing and marketing of diverse range of pharmaceutical formulations, herbal remedies and APIs.

Milestones & awards

1996-97

Shri. Dinesh Mody, Director, JBCPL, receiving the Prestigious National Export Award/Trophy for the year 1996-97, from the Hon’ble Prime Minister of India, Shri. Atal Behari Vajpayee

1999

J. B. Chemical & Pharmaceuticals Ltd. is honoured with the IDMA Quality Excellence Award: ‘Certificate of Merit’ for distinction in quality manufacturing at its manufacturing unit in Panoli.

2000

Company awarded a Golden Status certificate by the Govt. of India.

2001

J.B. Chemical & Pharmaceuticals Ltd. receives CHEMEXCIL’s ‘First Award’ for Outstanding Export Performance of Pharmaceuticals in the large-scale manufacturer’s category. Received South Africa MCA approval for its tablets facility at Panoli.

2003

First ANDA filing with USFDA for Ciprofloxacin.
First company to market Rantac CD.
Approval from Columbian Drug Regulatory Authority INVIMA for its state-of-the-art facility at Panoli.

2004

Features in the Forbes Global list 100 for “Best under $1 Billion” in Asia-Pacific.
Receives its maiden USFDA approval to market Ciprofloxacin tablets in the US market.
UKMHRA approves JBCPL’s tablet manufacturing facility at Panoli.

2005

TGA Australia approves JBCPL’s tablet manufacturing facilities at Panoli, Gujarat, India.
JBCPL receives USFDA approval to market Fluconazole tablets in the US market.
JBCPL features in Forbes Asia Pacific 200 List for “Best under a Billion” for second year in a row.

2006

The ‘Niryat Shree’ Certificate of Excellence was awarded to Unique Pharmaceutical Laboratories Limited, a division of JBCPL, by the Federation of Indian Export Organisations (FIEO) for outstanding export performance in the category of Chemicals, Drugs, Pharma & Allied Products, Non-SSI for the year 2004-05.

2007

JBCPL’s Annual Report for the year ended March 31, 2005 was awarded a merit certificate by the South Asian Federation of Accountants (SAFA), an apex body of SAARC, for the Best Presented Accounts for the year 2005 in the category of “Hospitality, Health, Transport, Shipping, etc.’

2008

Made a strategic investment in a company in South Africa called Biotech Laboratories.

2011

Divested the OTC portfolio in Russia, Ukraine and CIS to J&J.

2016

Resignation of a director - Dr. Niranjan Maniar due to health problem.

2017

Shri J. B. Mody, Chairman, receives Lifetime Achievement Award.
Mr. J. B. Mody’s Lifetime Achievement Award AV on 13-11-2017.

2018

US FDA has approved Company's Abbreviated New Drug Application (ANDA) for Midodrine Hydrochloride Tablets USP 2.5 mg, 5 mg. and 10 mg. (for treatment of orthostatic hypotension).

2020

This is to inform you that US FDA has approved Company's Abbreviated New Drug Application (ANDA) for Carbamazepine Extended Release Tablets USP 100 mg, 200 mg and 400 mg.